[{"address1": "240 East Grand Avenue", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 388 5600", "website": "https://www.oricpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 107, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard A. Heyman Ph.D.", "age": 66, "title": "Co-Founder, Independent Chairman & Member of Scientific Advisory Board", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 93000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jacob M. Chacko M.B.A., M.D.", "age": 44, "title": "President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 961003, "exercisedValue": 0, "unexercisedValue": 8457933}, {"maxAge": 1, "name": "Mr. Dominic G. Piscitelli CPA, M.B.A.", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 654742, "exercisedValue": 0, "unexercisedValue": 1012054}, {"maxAge": 1, "name": "Dr. Pratik S. Multani M.D., M.S.", "age": 56, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 715220, "exercisedValue": 0, "unexercisedValue": 2435303}, {"maxAge": 1, "name": "Dr. Charles L. Sawyers B.A., M.D., Ph.D.", "age": 64, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott W. Lowe Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lori Sickels Friedman Ph.D.", "age": 59, "title": "Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christian V. Kuhlen Esq., J.D., M.D.", "age": 50, "title": "General Counsel", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Iazzetti", "title": "VP & Head of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edna  Chow Maneval", "age": 63, "title": "Senior Vice President of Clinical Development", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.59, "open": 9.63, "dayLow": 9.36, "dayHigh": 9.91, "regularMarketPreviousClose": 9.59, "regularMarketOpen": 9.63, "regularMarketDayLow": 9.36, "regularMarketDayHigh": 9.91, "beta": 1.109, "forwardPE": -4.5358853, "volume": 224923, "regularMarketVolume": 224923, "averageVolume": 557912, "averageVolume10days": 341230, "averageDailyVolume10Day": 341230, "bid": 9.43, "ask": 9.52, "bidSize": 200, "askSize": 300, "marketCap": 668742848, "fiftyTwoWeekLow": 5.27, "fiftyTwoWeekHigh": 16.65, "fiftyDayAverage": 9.53, "twoHundredDayAverage": 9.945725, "currency": "USD", "enterpriseValue": 399833344, "floatShares": 42716996, "sharesOutstanding": 70542496, "sharesShort": 12859608, "sharesShortPriorMonth": 11379172, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1823, "heldPercentInsiders": 0.091309994, "heldPercentInstitutions": 0.97037005, "shortRatio": 24.2, "shortPercentOfFloat": 0.1851, "bookValue": 4.469, "priceToBook": 2.12128, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -110782000, "trailingEps": -1.76, "forwardEps": -2.09, "enterpriseToEbitda": -3.223, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ORIC", "underlyingSymbol": "ORIC", "shortName": "Oric Pharmaceuticals, Inc.", "longName": "ORIC Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1587735000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "dc096b5b-6f44-3289-9c72-d0a4b5607b05", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.48, "targetHighPrice": 25.0, "targetLowPrice": 13.0, "targetMeanPrice": 18.57, "targetMedianPrice": 18.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 286406016, "totalCashPerShare": 4.06, "ebitda": -124064000, "totalDebt": 9737000, "quickRatio": 14.658, "currentRatio": 15.077, "debtToEquity": 3.22, "returnOnAssets": -0.25195998, "returnOnEquity": -0.38789, "freeCashflow": -59144124, "operatingCashflow": -99726000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]